Stifel Maintains Hold on ACADIA Pharmaceuticals, Lowers Price Target to $21
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Paul Matteis maintains a Hold rating on ACADIA Pharmaceuticals (ACAD) and lowers the price target from $26 to $21.
May 09, 2024 | 1:53 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Stifel analyst Paul Matteis maintains a Hold rating on ACADIA Pharmaceuticals and lowers the price target from $26 to $21.
The reduction in price target by Stifel from $26 to $21, while maintaining a Hold rating, suggests a negative outlook on the stock's short-term price potential. This adjustment reflects analyst expectations of lower future performance or valuation, which could lead to decreased investor confidence and a potential decrease in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100